Sukumar Nagendran

Previous Company: Alnylam Pharmaceuticals

Sukumar Nagendran is the current director at Taysha Gene Therapies. Prior to their current position, Nagendran held various positions at different companies including Project Healthy Minds, Jaguar Gene Therapy, Medocity, Inc., Neurogene, Inc., Chardan, Saliogen, RTW Investments SPAC, Encoded Therapeutics, Solid Biosciences, and Alnylam Pharmaceuticals.

Nagendran has always been interested in the field of gene therapy and has dedicated their career to finding new and innovative ways to treat diseases. Sukumar is a highly skilled and experienced scientist who has made significant contributions to the field of gene therapy. Sukumar's work has helped to improve the lives of many people suffering from various diseases.

Sukumar Nagendran's educational career includes training in medicine at the Mayo Clinic in Rochester, MN, and a mini MBA program in biopharma innovation at Rutgers Business School. Sukumar also has a certification in executive education for leaders from The Wharton School and a residency in internal medicine from Mayo Clinic Graduate School of Biomedical Sciences. In addition, they have an MD from Rutgers Robert Wood Johnson Medical School and a BA from Rutgers University. Sukumar also completed the advanced level exam in zoology, chemistry, physics and pure math at Royal College.